Analyst Andrew Fein of H.C. Wainwright reiterated a Buy rating on Fulcrum Therapeutics, retaining the price target of $12.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Andrew Fein’s rating is based on the promising preclinical data presented by Fulcrum Therapeutics for their EED inhibitor, FTX-6274, in treating castration-resistant prostate cancer (CRPC). The compound has demonstrated significant tumor growth inhibition and extended survival in preclinical models, suggesting strong potential for future clinical success.
Additionally, the advancement of FTX-6274 into solid tumor indications represents a strategic expansion for Fulcrum beyond its traditional focus, which could enhance the company’s long-term growth prospects. The continued progress of Fulcrum’s lead asset, pociredir, in sickle cell disease, further supports the company’s valuation, providing a solid foundation complemented by a growing pipeline. These factors collectively underpin Fein’s Buy rating and the $12 price target for Fulcrum Therapeutics.
According to TipRanks, Fein is a 5-star analyst with an average return of 26.0% and a 53.25% success rate. Fein covers the Healthcare sector, focusing on stocks such as Alector, BioCryst, and United Therapeutics.
In another report released on October 8, Leerink Partners also reiterated a Buy rating on the stock with a $16.00 price target.